Immune Determinants of Infectious Reactivations After Cellular Therapies

Infectious complications including reactivation of latent infections are well-recognized complications following both allogeneic and (to a lesser extent) autologous hematopoietic cell transplantation (HSCT), and are increasingly being encountered in autologous cellular immune therapy of cancer. Though agreed risk factors include decreased immune effector cell function from immunosuppression (allogeneic HSCT) and conditioning regimens (HSCT and cellular cancer immunotherapy), the role of gnomic immune determinants in susceptibility has been poorly delineated.This Research Topic focuses our attention on associations and potential causative roles of genomic immunologic loci in reactivation of latent infections after HSCT and cellular immune therapies. We invite submissions of original research articles with subject matter centering on human and preclinical animal basic immunology and/or genomics, clinical trial-associated outcomes, and population science research on the role of specific genetics or epigenetics with susceptibility to viral, fungal, bacterial, and parasitic infections following cellular therapies. Studies with clinical outcome associations are especially encouraged, as are studies which seek to differentiate treatment-associated immune suppression from primary immune associations. Topic editors: Asha Bhaskaran Pillai, Zainab Shahid Source: https://www.frontiersin.org/research-topics/85381/immune-determinants-of-infectious-reactivations-after-cellular-therapies